Corten Capital and Ampersand Capital Partners have completed the purchase of Beacon Intelligence from the Hanson Wade Group, a firm backed by Graphite Capital. Beacon supplies structured data on early‑stage drug development across 16 modules, serving more than 300 customers worldwide. The acquisition adds a high‑growth data asset to Corten’s life‑science portfolio.

The deal is the third investment from Corten Capital II, which closed in March 2024 with €680 million committed. Ampersand joins as a minority co‑investor, spreading risk while keeping control of Beacon’s platform. This mirrors a trend of lead investors pairing with specialist partners to deepen sector expertise.

Beacon’s 300‑plus client base includes pharma firms and CROs that rely on timely, structured insights to de‑risk pipelines. Ownership by Corten and Ampersand should accelerate product development and open cross‑sell opportunities within their broader health‑tech holdings. The capital boost also enables expansion into emerging modalities like gene‑editing and cell‑based therapies, underscoring private‑equity focus on niche data providers that sharpen R&D efficiency.

The transaction closes a year of heightened activity in biotech data M&A, signaling investors’ confidence in the sector’s growth trajectory.